| Q40690704 | Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells |
| Q56883881 | An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration |
| Q43919448 | Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro |
| Q48729861 | Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects |
| Q43873811 | Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum |
| Q48287496 | Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. |
| Q30471565 | Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease |
| Q77093965 | Hydroxyl radicals and nitric oxide in neurotoxicity and neuroprotection |
| Q37171839 | In vivo evidence of increased nNOS activity in acute MPTP neurotoxicity: a functional pharmacological MRI study |
| Q37735813 | In vivo microdialysis in Parkinson's research. |
| Q64821231 | Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate |
| Q36745271 | Mitochondria in neurodegeneration |
| Q30471061 | Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions |
| Q30471062 | Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment |
| Q52563440 | Nitric oxide donors protect cultured rat astrocytes from 1-methyl-4-phenylpyridinium-induced toxicity. |
| Q40858367 | Nitric oxide induces differentiation in the NB69 human catecholamine-rich cell line |
| Q34348724 | Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury |
| Q44546955 | Reduction of energy metabolism in rat hippocampus by arginine administration |
| Q37597604 | Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity |
| Q56969444 | Role of nitric oxide in the ethylcholine aziridinium model of delayed apoptotic neurodegeneration in vivo and in vitro |
| Q31797525 | The effects of nitric oxide on the oxidations of l-dopa and dopamine mediated by tyrosinase and peroxidase |
| Q30473178 | The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. |
| Q34440280 | The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases |
| Q41757009 | The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention |